Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
327.70
-0.17 (-0.05%)
Mar 31, 2025, 1:23 PM EDT - Market open
Madrigal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Madrigal Pharmaceuticals stock have an average target of 354.75, with a low estimate of 150 and a high estimate of 469. The average target predicts an increase of 8.25% from the current stock price of 327.70.
Analyst Consensus: Buy
* Price targets were last updated on Feb 27, 2025.
Analyst Ratings
The average analyst rating for Madrigal Pharmaceuticals stock from 10 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 3 |
| Buy | 6 | 6 | 6 | 6 | 6 | 4 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 14 | 14 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $378 → $469 | Strong Buy | Maintains | $378 → $469 | +43.12% | Feb 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $400 → $405 | Strong Buy | Maintains | $400 → $405 | +23.59% | Feb 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $390 → $400 | Strong Buy | Maintains | $390 → $400 | +22.06% | Jan 14, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $427 | Buy | Reiterates | $427 | +30.30% | Jan 10, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Nov 20, 2024 |
Financial Forecast
Revenue This Year
571.11M
from 180.13M
Increased by 217.05%
Revenue Next Year
1.06B
from 571.11M
Increased by 84.73%
EPS This Year
-13.81
from -21.90
EPS Next Year
3.24
from -13.81
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 719.6M | 1.4B | 2.5B | ||
| Avg | 571.1M | 1.1B | 1.9B | ||
| Low | 302.3M | 508.4M | 1.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 299.5% | 150.0% | 139.1% | ||
| Avg | 217.0% | 84.7% | 77.3% | ||
| Low | 67.8% | -11.0% | 39.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -9.41 | 16.38 | 45.34 | ||
| Avg | -13.81 | 3.24 | 31.22 | ||
| Low | -25.82 | -21.46 | 6.61 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,301.3% | ||
| Avg | - | - | 865.0% | ||
| Low | - | - | 104.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.